Video

Dr. Popat on Unmet Needs in Triple-Class Refractory Multiple Myeloma

Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD, discusses unmet needs in triple-class refractory multiple myeloma.

Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD, consultant hematologist, University College Hospital, honorary clinical senior lecturer, University College London Cancer Institute, North Thames Clinical Research Network Specialty Lead for Hematology, Cancer Division, discusses unmet needs in triple-class refractory multiple myeloma.

Despite significant advancements that have been made over the past decade, multiple myeloma remains an incurable hematologic malignancy, Popat says. Currently, a major challenge in myeloma involves developing novel treatments for patients with triple-class refractory disease, Popat explains.

These heavily pretreated patients have progressed on or become intolerant of proteasome inhibitors, immunomodulatory agents, and CD38-directed monoclonal antibodies, says Popat.

These 3 drug classes have been brought into earlier lines of treatment in combination regimens for patients with multiple myeloma. Therefore, limited treatment options are available for patients with heavily pretreated progressive disease, concludes Popat.

Newsletter

Stay up to date on the most recent and practice-changing oncology data

Latest CME

View All
Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation
Video

Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation

Jun 6th 2025 - Jul 12th 2025

online-activity
Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC
Video

Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC

Jun 6th 2025 - Jul 12th 2025

online-activity
Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing
Video

Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing

Jun 5th 2025 - Jul 12th 2025

online-activity